Hussien O. Kadi*1, Mohammed H. Kadi2 and Taha H. Kadi3
1Yemen University, Faculty of Medical Sciences, Sana’a, Yemen
2Yemen University, Faculty of Medical Sciences and 48 Hospital, Sana’a, Yemen
3Yemen University, Faculty of Medical Sciences, Sana’a, Yemen
Abstract:
Introduction: Erectile dysfunction (ED) is a prevalent disorder affecting millions of men worldwide, with significant implications on quality of life and psychological well-being. The aim of this study was to evaluate the efficacy, safety, and tolerability of Seldiflexe, a novel oral gel sachet formulation of sildenafil citrate (12.5 mg in 5 g Yemeni honey), in comparison with standard sildenafil tablets (25 mg).
Methods: A randomized, double-blind, controlled trial was conducted on 80 male patients diagnosed with erectile dysfunction (ED). Patients were allocated to two groups: Seldiflexe sachet (n=40) or standard sildenafil tablet (n=40) for 4 weeks. Primary endpoints included improvement in the International Index of Erectile Function (IIEF) scores, onset of action, and adverse event profile. Results: demonstrated that Seldiflexe produced a significantly faster onset of action (mean 30 ± 5 min vs 50 ± 8 min, p<0.01) and improved tolerability, while maintaining comparable efficacy to standard tablets. This study suggests that Seldiflexe is a safe, effective, and patient-friendly alternative for the treatment of ED.
Conclusion: Seldiflexe (sildenafil 12.5 mg in Yemeni honey oral gel sachet) is a safe, effective, and well-tolerated alternative to conventional sildenafil 12.5 mg tablets for ED treatment. Its faster onset and better patient acceptability make it a promising innovation in sexual medicine.
Key words: Seldiflexe, Yemeni, Honey, Oral, Gel, Seldinafil
yemenuniversityjournal.net 